Glossary: UK Glossary

Search & Filter Results
Loading...
Academic Health and Science Networks (AHSN)

An organisation which helps align education, clinical research, informatics, innovation, training and education and healthcare delivery. The AHSN’s goal is to improve patient and population health outcomes by translating research into practice, and developing and implementing integrated health care services.

Acute Trust (AT)

Some hospitals in England are managed by acute trusts, some of which have also gained foundation trust status. Acute trusts ensure that hospitals provide high-quality healthcare and check they spend their money efficiently. They also decide how a hospital will develop to improve services. Acute trusts can also provide services in the community.

Most hospitals in England are now managed by NHS foundation trusts. Foundation Trusts are independent legal entities and have unique governance arrangements. They have financial freedoms and can raise capital from both the public and private sectors within borrowing limit.

All Wales Medicines Strategy Group (AWMSG)

The AWMSG is the Welsh health technology appraisal (HTA) body,  a statutory advisory Welsh Assembly-sponsored public body which aims to provide advice on medicines management and prescribing to the Welsh Government’s Minister for Health and Social Services in an effective, efficient and transparent manner.

All Wales Prescribing Advisory Group (AWPAG)

AWPAG is a subgroup of AWMSG. AWPAG advises the All Wales Medicines Strategy Group (AWMSG) on strategic developments in prescribing and medicines management to promote the safe and effective use of medicines in Wales.

The main functions of the group:

  • Develop and implement strategies that promote safe, rational, cost-effective prescribing
  • Monitor prescribing patterns and develop appropriate indicators
  • Advise on appropriate training, education and professional development for those persons employed in providing prescribing advice
  • Advise on the impact of developments that involve the use of medicines
  • Working in collaboration with other groups and organisations to promote the best use of medicines for patients

Appraisal Committee

An independent committee that develops NICE’s guidance on using drugs or treatments in the NHS (called technology appraisal guidance). It is made up of healthcare professionals and NHS managers, researchers, lay representatives, and people who work for drug companies and medical equipment manufacturers.

Appraisal Consultation Document (ACD)

The ACD sets out the Appraisal Committee’s provisional recommendations to NICE on how the technology should be used in the NHS in England.

It is the Appraisal Committee’s draft guidance on using a drug (or group of drugs) or treatment in the NHS (called technology appraisal guidance). The manufacturer and organisations who have been invited as consultees and commentators can comment on this draft guidance.

The ACD will include any restrictions in the event that a restrictive recommendation has been made by NICE.

Area Drugs and Therapeutics Committee (ADTC)

Committees responsible for providing advice to the regional NHS boards in Scotland on the use of medicines to meet the needs of the patients in that health board area. There are 14 regional health boards in Scotland.

Area Prescribing Committee (APC)

A local formulary decision-making group that is based in primary care.

Assessment Group

An independent assessment group commissioned by the NHS Research and Development Health Technology Assessment (HTA) programme to produce an independent review of the evidence for technologies being appraised within the multiple technology appraisal (MTA) process.

Assessment Report

A critical review of the clinical and cost effectiveness of a health technology or technologies being appraised within the multiple technology appraisal (MTA) process. It is prepared by the Assessment Group. To prepare the report, the Assessment Group carries out a review of the published literature and the submissions from manufacturers and sponsors.

Association of the British Pharmaceutical Industry (ABPI)

The ABPI is the trade association for more than 90 companies in the UK producing prescription medicines for human use.

BioIndustry Association (BIA)

The UK BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. The BIA works to further the interests of members and the industry – nationally and internationally.

British National Formulary (BNF)

Publications which evaluate clinical evidence from diverse sources with information validated by a network of clinical experts. BNF Publications reflect current best practice as well as legal and professional guidelines relating to the uses of medicines.

Business, Innovation & Skills (BIS)

The Department for Business, Innovation & Skills (BIS) is the department for economic growth. The department invests in skills and education to promote trade, boost innovation and help people to start and grow a business. BIS also protects consumers and reduces the impact of regulation.

Cancer Drug Fund (CDF)

The CDF is a centralised process that offers a route to funding in England for cancer medicines.

Centre Director

The Director of the Centre for Health Technology Evaluation is responsible for the delivery of the technology appraisal programme. The Director is also responsible for ensuring that appraisals are conducted in accordance with the published appraisal process and methodology.

Centre for Health Technology Evaluation (CHTE)

The centre at NICE that is responsible for producing technology appraisals, and interventional procedure, medical technology and diagnostics guidance. The guidance is developed by independent committees.

Technology appraisal guidance makes recommendations on the use of new and existing technologies in the NHS. Interventional procedure guidance evaluates the safety and efficacy of procedures used for diagnosis or treatment. The Medical Technologies Programme evaluates innovative medical technologies. The Diagnostics Assessment Programme evaluates diagnostic technologies.

Citizens Council

A group of 30 people drawn from all walks of life who bring the public’s views to NICE decision-making. The Citizens Council tackles challenging questions about values, such as fairness and need.

Clinical Commissioning Group (CCG)

Clinically-led statutory NHS bodies responsible for the planning and commissioning of health care services for their local area. CCGs were created in 2012 by the Health and Social Care Act (H&SC) and replaced the Primary Care Trusts in 2013.

Clinical Effectiveness Team (CET)

A small national team which procures high quality information that supports the development of commissioning policies.

Clinical Priorities Advisory Group (CPAG)

Advisory group that make recommendations on NHS England’s approach to commissioning services, treatments and technologies.

Clinical Reference Group (CRG)

CRGs are bring together groups of clinicians, commissioners, public health experts, patients and carers. There are tasked with the overall responsibility of ensuring that service specifications and clinical commissioning policies are delivered on time and to a high quality standard. They use their specific knowledge and expertise to advise NHS England on the best ways that specialised services should be provided . CRGs will provide advice on the development of service specifications, commissioning policies, identifying innovation and improving quality.

CRGs are based around the six National Programmes of Care (NPoC), establishing to cover the full range of specialised serviced defined within NHS England’s mandate.

Clinical Specialist

In technology appraisals, clinical specialists act as expert witnesses to the Appraisal Committee. They are selected on the basis of specialist expertise and personal knowledge of the technology and/or other treatments for the condition. They provide a view of the technology within current clinical practice, and insights not typically available in the published literature.

,

Clinically Critically Urgent (CCU)

Clinically critically urgent (CCU) procedures are used to consider funding requests for specialised services (drugs, devices and other clinical interventions) that are not routinely funded by the NHS, made on behalf of individuals who do not meet the criteria for an Individual Funding Request (IFR) and who present with critically clinically urgent circumstances.

Clinician and Patient Involvement Group (CAPIG)

CAPIG is part of the All Wales Medicines Strategy Group (AWMSG) health technology appraisal (HTA) process for new orphan/ultra-orphan medicines and medicines used to treat a rare disease. The aim of CAPIG is to identify and discuss in more detail any additional benefits of the medicine from both a clinician and patient perspective. The additional information gathered for CAPIG (the CAPIG report) will be presented to AWMSG and this will help AWMSG make a decision that takes greater account of the patient and clinician perspective.

Commentator

An organisation that engages in the appraisal process but is not asked to prepare a submission dossier. Commentators are invited to comment on the draft scope document, the assessment report and the appraisal consultation document (ACD). They receive the final appraisal determination (FAD) for information only. These organisations are manufacturers of comparator technologies, Healthcare Improvement Scotland (HIS), the relevant National Collaborating Centre, related research groups, and other groups when appropriate.

Commercial Medicines Unit (CMU)

The CMU team work in partnership with the people who buy pharmaceuticals for hospitals across the NHS in England. In particular, it works with NHS pharmacists and suppliers to gather and analyse the money spent on secondary care (hospital) medicines. CMU works on behalf of both the Department of Health and Social Care (DHSC)  and the NHS.

Committee Papers

The committee papers that are issued and published with an appraisal consultation document (ACD) or a final appraisal document (FAD) include all of the evidence seen by the Appraisal Committee. It is made up of the ERG report, written submissions, and the personal statements of patient experts and clinical specialists, as well as comments received on the ERG report. For second and subsequent committee meetings they will also include consultation comments and responses.

,

Decision Support Unit (DSU)

The Decision Support Unit helps the technical team at NICE to meet the information needs of the Appraisal Committee. This is achieved by providing support, as required, to the technical team and the Evidence Review Group. The objective of the Decision Support Unit is to enhance the delivery of robust information to support Appraisal Committee decision-making. The Decision Support Unit is a multidisciplinary team, expert in methods of health technology appraisal and capable of providing advice and high-quality analyses to decision-makers within very tight deadlines.

Department of Health (DoH), Northern Ireland

A devolved Northern Irish government department in the Northern Ireland Executive, with the aim to improve the health and social well-being of the people of Northern Ireland.

Department of Health and Social Care (DHSC)

The Department of Health and Social Care (DHSC) is responsible for standards of healthcare in the UK, including the NHS. The Department sets the strategic framework for adult social care and influences local authority spending on social care. The Department is also responsible for promoting and protecting the public’s health, taking the lead on issues like environmental hazards to health, infectious diseases, health promotion and education, the safety of medicines, and ethical issues.

Early Access to Medicines (EAMS)

EAMS is a system which aims to provide patients that have seriously debilitating or life-threatening conditions, access to medicines which do not yet possess marketing authorisation when there is a clear unmet medical need.

Ethical Medicines Industry Group (EMIG)

EMIG is a UK research-based trade association that represents the interests of small to medium-sized Pharmaceutical, Biotech and Medtech companies (SMEs).

Evidence Review Group (ERG)

An independent assessment group commissioned by the NHS Research and Development Health Technology Assessment (HTA) programme to produce an independent assessment of the evidence submitted by the manufacturer or sponsor of a technology being appraised within the single technology appraisal (STA) process.

Evidence Review Group Report

A critical assessment of the evidence submitted by the manufacturer of a technology being appraised within the single technology appraisal (STA) process. It is prepared by the Evidence Review Group.

Final Appraisal Determination (FAD)

The FAD sets out the Appraisal Committee’s final recommendations to NICE on how the technology should be used in the NHS in England.

Greater Manchester Medicines Management Group (GMMMG)

The GMMMG is a coordinating group (consisting of GPs, pharmacists and other key healthcare professionals) for decision making around medicines and in particular high cost medicines for Greater Manchester. It also has a role in performance monitoring of health economies prescribing.

Guidance Executive

A team comprising the Executive Directors and Centre Directors at NICE who are responsible for approving the final appraisal determination before publication.

Health and Safety Executive (HSE)

The UK body responsible for regulation and enforcement of workplace health, safety and welfare through the Health and Safety at Work etc. Act 1974.

Health and Social Care (HSC/H&SC)

In the UK, Health and Social Care (HSC or H&SC) is a term that relates to services that are available from health and social care providers. It is a generic term used to refer to the whole of the healthcare provision infrastructure, public and private sector.

Health Products Regulatory Authority (HPRA)

Formerly known as the Irish Medicines Board (IMB), the regulatory body in Ireland whose role it is to protect and enhance public and animal health by regulating medicines, medical devices and other health products.

Health Technology Assessment (HTA)

The systematic evaluation of properties, effects, and/or impacts of health technology. It is a multidisciplinary process to evaluate the social, economic, organisational and ethical issues of a health intervention or health technology. The main purpose of conducting an assessment is to inform a policy decision making for a drug, medical device or clinical/surgical procedure.

Healthcare Improvement Scotland (HIS)

The national healthcare improvement organisation for Scotland. The SMC is part of HIS.

HIS has a key role in supporting healthcare providers to make sure that their services meet these expectations and continually improve the healthcare the people of Scotland receive.

Highly Specialised Technology (HST)

HST evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS in England. The HST programme only considers drugs for very rare conditions and notify the DHSC of key, new and emerging healthcare technologies that might need to be referred to NICE.

Horizon Scanning

The process of identifying new medicines or new uses of existing medicines that are expected to receive marketing authorisation from the Medicines and Healthcare products Regulatory Authority (MHRA) or the European Medicines Agency (EMA) in the near future and estimating their potential impact on patient care.

Individual Funding Requests (IFR/IPFR/IPTR)

An individual funding request is a special request that can be made by your clinician (doctor or other health professional) if they believe that a particular treatment or service that is not routinely offered by the NHS is the best treatment for you, given your individual clinical circumstances.

Joint Committee on Vaccinations and Immunisations (JCVI)

The Joint Committee on Vaccination and Immunisation (JCVI) advises UK health departments on matters relating to communicable diseases which are preventable or potentially preventable through immunisation.

The JCVI also makes recommendations to the British government concerning vaccination schedules and vaccine safety.

Local Authority (LA)

Some therapy areas are managed partly by health authorities (e.g. CCGs, NHSE) and partly by local council authorities e.g. public health is largely funded through local authorities.

Local Health Boards (LHB)

An administrative unit within the National Health Service in Wales. There are 7 LHBs which plan, secure and deliver healthcare services in their areas, replacing the 22 LHBs and the 7 NHS Trusts.

,

Managed Entry Agreements (MEA)

MEAs are schemes designed to reduce these costs. MEAs have been used by decision makers to recommend technologies under two broad conditions:

  1. That the price of the technology be reduced and / or
  2. That further research be conducted. Both conditions have the aim of reducing risk and decision uncertainty

Medical Innovation Briefing (MIB)

MIBs help support NHS and social care commissioners and staff who are considering using new medical devices and other medical or diagnostic technologies. They include a description of the technology, how it’s used and its potential role in the treatment pathway.

A MIB also includes a review of relevant published evidence and the likely costs of using the technologies. They are designed to be fast, flexible and responsive to the need for information on innovative technologies.

Medicines and Healthcare Products Regulatory Agency (MHRA)

The Executive Agency of the Department of Health and Social Care (DHSC). It protects and promotes public health and patient safety by ensuring that medicines, healthcare products and medical equipment meet appropriate standards of safety, quality, performance and effectiveness, and are used safely.

Medicines Evaluation Committee (MEC)

A sub-group of the Area Prescribing Committee (APC) to conduct specific evaluation reports of a new medicine.

Mental Health Trust (MHT)

A MHT provides health and social care services for people with mental health disorders in England.

Named Patient Programs (NPP)

Named patient programs (NPP) provide controlled, pre-approval access to drugs in response to requests by physicians on behalf of specific, or “named”, patients before those medicines are licensed in the patient’s home country.

Through these programs, patients are able to access drugs in late-stage clinical trials or approved in other countries for a genuine, unmet medical need, before those drugs have been licensed in the patient’s home country.

,

National Health Service (NHS)

The NHS is the name commonly used to refer to the publicly funded healthcare systems of the UK.

National Hospitals Office (NHO)

National Hospitals Office (NHO) are responsible for the management and co-ordination of the acute hospital sector nationally in Ireland.

National Institute for Care and Excellence (NICE)

NICE are a public body of the Department of Health and Social Care (DHSC) in the UK which provides national guidance and advice to improve health and social care. NICE also develop guidance, standards and information on high quality health and social care.

National Institute for Health Research – Health Technology Assessment Programme (NIHR HTA)

The National Institute for Health Research – Health Technology Assessment (NIHR HTA) is part of the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) based at the University of Southampton. The NIHR HTA coordinates the Health Technology Assessment (HTA) Programme on behalf of the NIHR. The aim of the HTA Programme is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way.

National Institute for Health Research (NIHR)

Funded by the Department of Health and Social Care (DHSC), the NIHR aims to improve the health and wealth of the nation through research, driving faster research translation from bench to bedside for the benefit of patients and the economy.

National Programmes of Care (NPoC)

National Programmes of Care are strategies which group together the prescribed (nationally agreed range of) specialised services. These strategies will enable the commissioning of services to be based on clear evidence and ensure that they are cost effective and patient focused.

The six NPoC’s are:

– Internal medicine – digestion, renal, hepatobiliary and circulatory system
– Cancer
– Mental health
– Trauma – traumatic injury, orthopaedics, head and neck and rehabilitation
– Women and children – women and children, congenital and inherited diseases
– Blood and infection – infection, immunity and haematology

New Drugs Committee (NDC)

Every medicine submitted to SMC is given initial consideration by the New Drugs Committee (NDC), a scientific sub-group who consider the clinical and economic evidence put forward by a company. The members of NDC are mostly healthcare professionals from area drug therapeutic committees (ADTCs). They make an initial recommendation on whether the medicine should be accepted for use in NHS Scotland or not. This recommendation is then presented at the SMC meeting. If the medicine is end of life, orphan or ultra-orphan and the NDC have not recommended it, then the medicine can be considered at a PACE meeting. The output of the PACE meeting is taken into consideration at the SMC meeting.

New Medicines Group (NMG)

NMG is a subgroup of the All Wales Medicines Strategy Group (AWMSG). Up to ten NMG meetings are scheduled per year, which are held in private. NMG considers the clinical and cost-effectiveness of a medicine, along with written evidence from the pharmaceutical company, clinical experts in the field and relevant patient organisation(s) / support group(s) / patient(s) / patient carer(s). NMG makes a preliminary recommendation to AWMSG in relation to each medicine undergoing appraisal.

NHS England (NHSE)

NHS England leads the NHS in England. It sets the priorities and direction of the NHS. It commissions the contracts for GPs, pharmacists, and dentists and supports CCGs.

Patient Access Scheme (PAS)

A scheme where an agreement is reached between a pharmaceutical company and the NHS in order to reduce the costs of a medicine and improve its cost-effectiveness. This can enable patients to receive access to cost-effective, innovative medicines.

Patient Access Scheme Assessment Group (PASAG)

The Patient Access Schemes (PAS) advisory group in Scotland. PASAG review and advise NHS Scotland on the feasibility of proposed PAS for implementation. It operates separately from the SMC to maintain the integrity and independence of the assessment process.

Patient Access Scheme Liaison Unit (PASLU)

PASLU is the Patient Access Schemes (PAS) advisory group in England. Part of the NICE Centre for Health Technology Evaluation that coordinates the review and evaluation of PAS proposals and produces guidance to the Department of Health and Social Care (DHSC).

Patient Access Scheme Wales Group (PASWG)

PASWG is the Patient Access Schemes (PAS) advisory group in Wales, which aids the reviewing process for PAS applications made to the All Wales Medicines Strategy Group (AWMSG) within the Health Technology Appraisal (HTA) process.

Patient and Clinical Engagement (PACE)

The PACE process gives patient groups and clinicians a stronger voice in SMC decision making for rare/orphan diseases. The main purpose of PACE is to gather detailed information which will allow a discussion on the benefits of a medicine, including how it can impact the quality of a patient’s life which may not be captured in within the conventional assessment process.

Patient Experts

Acts as an expert witness to the Appraisal Committee. Patient experts have used the technology either personally or as part of a representative group. They provide a view on the risks and benefits of the technology from personal experience as a patient or carer, and an understanding of the wider range of patient and/or carer views.

Pharmaceutical Price Regulation Scheme (PPRS)

The 2014 PPRS was a non-contractual scheme that was replaced on 1 January 2019 by the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (Voluntary Scheme). The parties to this agreement were the Department of Health and Social Care (DHSC), acting on behalf of the health departments of England, Wales, Scotland and Northern Ireland, and the Association of the British Pharmaceutical Industry (ABPI). The purpose of the scheme was to ensure that safe and cost-effective medicines were available on the NHS in England.

Prescribed Specialised Services Advisory Group (PSSAG)

The PSSAG is an expert committee within the Department of Health and Social Care (DHSC) which advises when services are specialised and should be directly commissioned nationally by NHS England rather than locally by CCGs.

Primary, Community and Continuing Care (PCCC)

Primary, Community and Continuing Care (PCCC) directorate are responsible for the management and delivery of non-hospital services in Ireland.

Promising Innovative Medicine (PIM)

The PIM designation provides an indication that a product may be eligible for the EAMS, based on early clinical data. Often, this PIM designation is issued after the MHRA has held a scientific meeting and this designation can be provided several years prior to the product being licensed.

Public Assessment Report (PAR)

public assessment report is published by the MHRA if you receive a positive EAMS scientific opinion.

The Public Assessment Report will include:

  • how the product is used and how it works
  • summary of the key clinical studies
  • the risks and benefits of the product
  • the reason for the positive EAMS scientific opinion
  • any uncertainties
  • information about ongoing clinical studies
  • measures in place to monitor and manage risk

Public Health England (PHE)

Public Health England (PHE) are an executive agency that delivers services to protect the public’s health through a nationwide integrated health protection service, provides information and intelligence to support local public health services, and supports the public in making healthier choices.

Public Involvement Programme (PIP)

The PIP is the team at NICE that supports and develops public involvement across NICE’s work programme. A PIP Public Involvement Adviser is assigned to each appraisal and supports patient and carer consultee organisations, their representatives, and individual patients or carers throughout the appraisal. The PIP public involvement adviser also supports the lay members of the Appraisal Committees and supplies the patient and carer group information for the ‘Information for the public’.

Rare Disease Advisory Group (RDAG)

RDAG receives recommendations from CRGs and calls on evidence from professional bodies and patient groups, then makes recommendations to UK nations and CPAG on development and implementation of rare disease and specialised services strategy.

Regional Drugs and Therapeutics Centre (RDTC)

RDTC is a commissioned service that provides strategic prescribing support services to Clinical Commissioning Groups, other primary care organisations, and NHS Hospital Trusts in the North of England.

Remit

This is the brief the Department of Health and Social Care (DHSC) gives to NICE when it formally refers a technology for appraisal. Typically, the remit outlines the disease, the patients and the technologies that will be covered by the appraisal.

,

Scottish Antimicrobial Prescribing Group (SAPG)

The Scottish Antimicrobial Prescribing Group (SAPG) delivers a national framework for improving the quality of antimicrobial prescribing in Scotland.

Scottish Intercollegiate Guidelines Network (SIGN)

SIGN provides evidence-based guidance on the diagnosis and management of specific conditions for the NHS in Scotland.

Scottish Medicines Consortium (SMC)

A consortium of stakeholders from NHS Boards and Area Drug and Therapeutic Committees (ADTCs) with representation derived from across NHS Scotland. The SMC  provides advice to all NHS Boards and their ADTCs about the status of all newly licensed medicines, all new formulations of existing medicines and any major new indications for established products. All new products must undergo an SMC evaluation within 3 months of launch.

Scottish Patient Safety Programme (SPSP)

The SPSP is a national plan that aims to improve the safety and reliability of healthcare and reduce harm whenever care is delivered.

Statutory Scheme

In 2008 the UK Government consulted on regulations to set up the statutory scheme, the purpose of which was to safeguard the financial position of the NHS by ensuring that there would be similar limits to the Pharmaceutical Price Regulation Scheme (PPRS) on the cost of branded health service medicines supplied by companies that decided not to join, or withdraw from, the PPRS. The statutory scheme’s policies may be changed at any time, subject to approval by Parliament. The statutory scheme was revised in 2018 and came into effect at the beginning of 2019.

Systematic Literature Review (SLR)

See ‘Systematic Review‘.

,

Technology Appraisal (Single: STA; Multiple: MTA)

The process of developing recommendations on the use of new and existing health technologies within the NHS in England. A multiple technology appraisal will normally cover more than 1 technology, or 1 technology for more than 1 indication. A single technology appraisal covers a single technology for a single indication.

Technology Assessment (TA)

The process of evaluating the clinical, economic and other evidence relating to the use of a technology and to formulate guidance on its use. See ‘HTA‘.

,

Terminated Appraisal

The single technology appraisal process relies on manufacturers or sponsors submitting evidence, in line with NICE’s specification. Occasionally, they do not make a submission or the submission does not meet the specification. The appraisal is therefore terminated and NICE asks NHS organisations to take into account the reasons why the manufacturer or sponsor did not make an evidence submission when making local decisions on whether to offer the treatment.

The Department of Health (DoH), Ireland

The Department of Health supports the Minister for Health and the Government by advising on the strategic development of the health system including policy and legislation and evaluating the performance of the health and social services.

UK Medicines Information (UKMi)

The UKMi is an NHS pharmacy based service aimed to support the safe, effective and efficient use of medicines by the provision of evidence-based information and advice on their therapeutic use.

The service has two broad functions:

  • to support medicines management within NHS organisations
  • to support healthcare professionals optimise use of medicines for individual patients

UK Trade & Investment (UKTI)

See ‘DIT‘.

Welsh Health Specialised Services Committee (WHSSC)

The Welsh Health Specialised Services Committee (WHSSC) is responsible for the joint planning of Specialised and Tertiary Services on behalf of Local Health Boards (LHBs) in Wales. Every year, WHSSC receives money from the LHBs to pay for specialised healthcare for everyone who lives in Wales and is entitled to NHS care.

The WHSSC was established to ensure that the population of Wales has fair and equitable access to the full range of specialised services. In establishing WHSSC to work on their behalf, the seven LHBs recognised that the most efficient and effective way of planning these services was to work together to reduce duplication and ensure consistency.

Sorry, no results for this search